SOMIT
Financiado
Leveraging a novel platform technology to develop a first in class immunotherapy...
Leveraging a novel platform technology to develop a first in class immunotherapy for Celiac Disease
Celiac Disease is a debilitating autoimmune disorder that is caused by intolerance to gluten. Although it is the most common genetically-based food intolerance in the world, there are currently no therapeutics available to treat p...
Celiac Disease is a debilitating autoimmune disorder that is caused by intolerance to gluten. Although it is the most common genetically-based food intolerance in the world, there are currently no therapeutics available to treat patients. In this project, Allero Therapeutics will collaborate with two leading research institutes (Leiden University Medical Center from the Netherlands and the Veterinary Research Institute from the Czech Republic) to develop a first-in-class therapeutic against Celiac Disease. Specifically, this novel therapeutic consists of an antigen-specific immunotherapy combined with tolerizing agents, which will be delivered to the oromucosa via a proprietary sublingual mouth patch. This project consists of a 6-month multi-disciplinary feasibility study that will:
(1) experimentally demonstrate in vitro and ex vivo Proof of Principle for the novel therapeutic;
(2) research all required (pre)clinical development to build a detailed roadmap for navigating the regulatory landscape;
(3) strengthen and expand the current IP position; and
(4) consolidate all current and future findings into an investor-ready Business Plan.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2018-08-01
Fecha Fin: 2019-02-28
Fecha Fin: 2019-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-02-28
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
ALLERO THERAPEUTICS
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
276.59K€ |
Participante